Results 121 to 130 of about 33,909 (239)

Rapamycin Reduces Amyloid‐β Plaques and Improves Behavioral Performance in a Sex‐Dependent Manner in Mouse Models of Amyloidosis

CNS Neuroscience &Therapeutics, Volume 32, Issue 3, March 2026.
Rapamycin treatment reduced cerebral Aβ plaque burden, alleviated neuritic dystrophy, suppressed glial hyperactivation, and increased plaque‐associated microglial recruitment in amyloidosis mouse models, resulting in improved memory performance. Mechanistically, rapamycin enhanced microglial lysosomal degradation, facilitated lipid droplet clearance in
Shihui Guo, Weishan Fu, Yating Wang, Qi Liu, Jiaxin Li, Kai Guo, Hongsheng Zhang   +6 more
wiley   +1 more source

Recent advances in understanding and treating immunoglobulin light chain amyloidosis [version 1; referees: 2 approved]

F1000Research, 2018
Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction.
Talha Badar, Anita D'Souza, Parameswaran Hari   +2 more
doaj   +1 more source

Lipid Nanoparticles in Drug Delivery: Overcoming Challenges and Unlocking New Frontiers

Small Structures, Volume 7, Issue 3, March 2026.
Lipid nanoparticles (LNPs) have revolutionized nucleic acid delivery, yet challenges in formulation, stability, and targeted efficacy persist. This review explores how advances in microfluidic manufacturing, precision targeting, and endosomal escape are reshaping LNP design.
Jordan Kambanis, Lauren A. Lowe, Jingyi Yao, Zhenxu Yang, Shaoxue Zeng, Ken‐Tye Yong, Ling Zhu, Yi Shen   +7 more
wiley   +1 more source

Systemic Light Chain Amyloidosis

New England Journal of Medicine
Minnema M, Schönland S.
europepmc   +6 more sources

Development of Renal Failure without Proteinuria in a Patient with Monoclonal Gammopathy of Undetermined Significance: An Unusual Presentation of AL Kappa Amyloidosis

Case Reports in Nephrology, 2012
AL amyloidosis complicating monoclonal gammopathy of undetermined significance (MGUS) has usually a predominant glomerular deposition of lambda light chain. Heavy proteinuria is one of its cardinal manifestations.
Yijuan Sun, Amarpreet Sandhu, Darlene Gabaldon, Jonathan Danaraj, Karen S. Servilla, Antonios H. Tzamaloukas   +5 more
doaj   +1 more source

Drug Product Development of Lipid Nanoparticle‐Based mRNA Therapeutics and Vaccines

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Overview of the development path from an mRNA–lipid nanoparticle (LNP) concept to a licensed drug product, covering LNP design, manufacturing process development, formulation, and analytical characterization. ABSTRACT Lipid nanoparticles (LNP) are currently the most relevant non‐viral delivery systems for mRNA and occasionally for smaller nucleic acids
Gideon Kersten, Eleonora Cerasoli, Bruce Kerwin, Olivia M. Merkel, Andrea Hawe   +4 more
wiley   +1 more source

Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG‐MM5 Trial

European Journal of Haematology, Volume 116, Issue 3, Page 226-234, March 2026.
ABSTRACT Response assessment during treatment of multiple myeloma (MM) typically relies on immunofixation and serum electrophoresis. However, low levels of IgG and especially IgA paraprotein are difficult to quantify reliably. The Hevylite Assay quantifies the kappa and lambda fractions of IgG and IgA separately and is useful to determine response to ...
Tim Richardson, Elias Mai, Ekaterina Menis, Axel Benner, Diana Tichy, Kaya Miah, Mathias Hänel, Britta Besemer, Amelie Boquoi, Igor Wolfgang Blau, Christian S. Michel, Hans Walter Lindemann, Snjezana Janjetovic, Peter Brossart, Helga Bernhard, Peter Reimer, Hans Salwender, Dirk Hose, Anja Seckinger, Marc Raab, Hartmut Goldschmidt, Christof Scheid, For the German‐Speaking Myeloma Multicenter Group (GMMG) HD5 Investigators, Koordinierungszentrum für Klinische Studien, KKS) Heidelberg, Facharztpraxis Hämatologie und Onkologie, Praxisnetzwerk Hämatologie/Internistische Onkologie, Facharztpraxis Onkologie, Caritas Krankenhaus Bad Mergentheim, MVZ Baden‐Baden, Charité Universitätsmedizin Berlin, Charité Universitätsmedizin Berlin, HELIOS Klinikum Berlin‐Buch, Medizinisches Versorgungszentrum, Facharztpraxis Onkologie, Onkologie Seestrasse, Klinikum Bielefeld Mitte, Facharztpraxis Onkologie, Universitätsklinikum Bonn, Johanniter Krankenhaus Bonn, Onkologie Rheinsieg, Städt. Klinikum Braunschweig, Onkologische Schwerpunktpraxis, Onkologische Praxis im Krankenhaus Buchholz, Onkologische Schwerpunktpraxis, Klinikum Chemnitz, Regiomed Kliniken GmbH, Carl‐Thiem‐Klinikum Cottbus, Klinikum Darmstadt, Onkologische Schwerpunktpraxis, Gemeinschaftspraxis für Hämatologie und Onkologie, Fachpraxis für Hämatologie und Onkologie, Universitätsklinikum Essen, Evangelisches Krankenhaus Essen‐Werden Zentrum für Innere Medizin, Universitätsklinikum Frankfurt, Agaplesion Medizinisches Versorgungszentrum, MVZ) Frankfurt, Krankenhaus Nordwest, Interdisziplinäres Facharztzentrum, IFS) Frankfurt, Vitanus GmbH, Frankfurter Rotkreuz‐Kliniken, PIOH‐Praxis für Internistische Onkologie und Hämatologie, Onkologische Facharztpraxis, Facharztpraxis für Hämatologie und Onkologie, Kath. Krankenhaus Hagen, Asklepios Klinik Altona, Asklepios Klinik St. Georg, Hämatologisch‐Onkologische Praxis Altona, Facharztpraxis für Hämatologie und Onkologie, OncoResearch Lerchenfeld UG, Evangelisches Krankenhaus Hamm gGmbH, Onkologische Schwerpunktpraxis, Klinikum Hanau GmbH, Klinikum Region Hannover, Onkologisches Ambulanzzentrum OAZ Hannover, Universitätsklinikum Heidelberg, Onkologische Schwerpunktpraxis, Onkologische Schwerpunktpraxis Heilbronn, SLK Kliniken Heilbronn GmbH, Facharztpraxis für Hämatologie und Tumorerkrankungen, Universitätsklinikum des Saarlandes, Klinikum Idar‐Oberstein, Schwerpunktpraxis für Hämatologie und Onkologie, Gemeinschaftspraxis für Hämatologie, Universitätsklinikum Köln, Onkologie Köln, Praxis Internistischer Onkologie und Hämatologie, Kliniken Köln, Facharztpraxis für Hämatologie, Onkologisches Zentrum Lebach, Klinikum der Stadt Ludwigshafen am Rhein, Onkologische Schwerpunktpraxis Lüneburg, Universitätsmedizin der Johannes Gutenberg‐Universität Mainz, MED Facharztzentrum, Universitätsmedizin Mannheim, Mannheimer Onkologie Praxis, Facharztpraxis für Innere Medizin, Praxis für Innere Medizin, AöR) Johannes Wesling Klinikum Minden, Kliniken Maria Hilf, Städtisches Klinikum München, Facharztpraxis für Innere Medizin, medius Kliniken, Onkologische Facharztpraxis, Paracelsus Kliniken, medius Kliniken, Medizinisches Versorgungszentrum am Siloah St. Trudbert‐Klinikum, Onkologische Praxis Pinneberg, Gemeinschaftspraxis Innere Medizin/Onkologie, Facharztpraxis für Onkologie, Diakonie‐Klinikum Schwäbisch Hall, Zaho‐Zentrum für ambulante Hämatologie und Onkologie, Diakonie Klinikum Jung‐Stilling, Gastroenterologie Onkologie Bodensee, Onkologische Schwerpunktpraxis Speyer, Marienhospital Stuttgart, Krankenhaus der Barmherzigen Brüder Trier, Klinikum Mutterhaus der Borromäerinnen Trier, Onkologische Schwerpunktpraxis am Brüderkrankenhaus Trier, Onkologie Rheinsieg, Universität Tübingen, OMM Optimed Mundial GmbH, Facharztpraxis für Onkologie, Ammerland Klinik, Facharztpraxis für Onkologie   +125 more
wiley   +1 more source

Enhanced Detection of Multiple Myeloma Cells by Next‐Generation Flow Cytometry Following Density Gradient Medium Separation

European Journal of Haematology, Volume 116, Issue 3, Page 256-266, March 2026.
ABSTRACT Introduction Following treatment, relapse of Multiple Myeloma (MM) occurs due to measurable residual disease (MRD). As therapeutic options expand, advances in response assessment become more critical, necessitating more sensitive MRD detection methods.
Aisling O'Brien, Vitaliy Mykytiv, Fiona O'Halloran   +2 more
wiley   +1 more source

Effects of gonadectomy on brain sex hormone levels and amyloid pathology in male and female AppNL‐G‐F and AppNL‐F mice

Journal of Neuroendocrinology, Volume 38, Issue 3, March 2026.
Abstract More women than men are diagnosed with Alzheimer's disease (AD). Sex hormones have been ascribed neuroprotective properties, and their decline, particularly the reduction of estrogen during menopause, has been implicated in AD risk. In this study, we examined how loss of circulating sex hormones affects cognitive performance and amyloid ...
Patricia Muñoz, Heba G. Ali, Aphrodite Demetriou, Maria Latorre‐Leal, Makoto Shimozawa, Ljerka Delac, Tudor‐Fabian Troncea‐Sandu, Jose Inzunza, Per Nilsson, Silvia Maioli, Ivan Nalvarte   +10 more
wiley   +1 more source

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Hereditary Transthyretin Amyloidosis Polyneuropathy

Journal of the Peripheral Nervous System, Volume 31, Issue 1, March 2026.
ABSTRACT Background and Aims In individuals with hereditary transthyretin amyloidosis (ATTRv) polyneuropathy, monitoring of disease progression and treatment response is crucial. The objective is to determine if serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) are reliable biomarkers of ATTRv polyneuropathy ...
Valentin Loser, Pascal Benkert, Alex Vicino, Nicolas Ghika, Pansy Lim Dubois Ferrière, Chantal Daigneault, Thierry Kuntzer, Aleksandra Maleska Maceski, Jens Kuhle, Marie Théaudin   +9 more
wiley   +1 more source